# DeLLphi-312 (NCT07005128)

> A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07005128
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Amgen
- Conditions: Small-cell Lung Cancer; Extensive Stage Small-cell Lung Cancer
- Interventions: Tarlatamab; Durvalumab; Carboplatin; Etoposide
- Enrollment: 350
- Primary outcome: Overall Survival (OS)
- Primary outcome: Progression free survival (PFS) (Blinded Independent Central Review [BICR] Assessed)

## Commentary we found

- YouTube: 7
- Podcasts: 5
- X threads: 5

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=dellphi-312-nct07005128

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT07005128", "email": "<work email>"}; the inbox owner confirms by the emailed link.